SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: EX-1.1
Date Filed: 2025-08-15
Accession Number: 0001213900-25-077458
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025077458/ea024071103ex1-1_synergy.htm

Chunk 11 of 19
Word Count: 1465
Character Count: 9190

Document Content:

of this clause. (xi) The Company represents and agrees that, unless it obtains the prior written consent of the Representative, it has not made and will not make any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus; provided that the prior written consent of the parties hereto shall be deemed to have been given in respect of the free writing prospectuses included in Schedule III. Any such free writing prospectus consented to by the Company and the Representative is hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company represents that it has treated or agrees that it will treat each Permitted Free Writing Prospectus as an “issuer free writing prospectus,” as defined in Rule 433, and has complied or will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely Commission filing where required, legending and record-keeping.

(xii) The
Company hereby agrees that, without the prior written consent of the Representative, it will not, during the period ending ninety
(90) days after the date hereof (“Lock-Up Period”), (i) offer, pledge, issue, sell, contract to sell, purchase,
contract to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock; or (ii) enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such
transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or
otherwise; or (iii) file any registration statement with the Commission relating to the offering of any shares of Common Stock or
any securities convertible into or exercisable or exchangeable for Common Stock, except for (A) a registration statement on Form S-8
with respect to the registration of shares of Common Stock to be issued pursuant to an equity incentive plan and (B) a
“shelf” registration statement on Form S-3, when the Company is eligible to use such form, with respect to the
registration of shares of Common Stock to be issued pursuant to an “at the market” facility. The restrictions contained
in the preceding sentence shall not apply to (1) the Shares to be sold hereunder, (2) the issuance of Common Stock upon the exercise
of options or warrants or the conversion of outstanding preferred stock or other outstanding convertible securities disclosed as
outstanding in the Registration Statement (excluding exhibits thereto), the Time of Sale Disclosure Package, and the Final
Prospectus, or (3) the issuance of employee stock options and the grant of restricted stock awards or restricted stock units or
shares of Common Stock pursuant to equity incentive plans.

(xiii) If the Representative,
in its sole discretion, agrees to release or waive the restrictions set forth in the Lock-Up Agreements described in Section 2(a)(xv)
for an officer or director of the Company and provide the Company with notice of the impending release or waiver at least three (3) business
days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release
substantially in the form of Exhibit C hereto through a major news service at least two (2) business days before the effective date of
the release or waiver.

(xiv) The Company
hereby agrees to engage and maintain, at its expense, a registrar and transfer agent for the Common Stock.

(xv) Subject to the
right of the Company to terminate this Agreement for cause pursuant to FINRA Rule 5110(g)(5)(B), the Representative shall be entitled
to the compensation set forth in this Agreement, calculated as set forth herein, including, without limitation, the underwriting discounts
and commissions and underwriter warrants, with respect to any public or private offering or other financing or capital raising transaction
of any kind to the extent such financial or capital is provided to the Company by investors introduced by the Representative to the Company
at any time within the 12-month period following the expiration or termination of that certain engagement letter dated July 28, 2025 between
the Company and the Underwriter relating to the Offering.

6. Conditions of the
Underwriter’s Obligations. The obligations of the Underwriters hereunder to purchase the Shares are subject to the accuracy,
as of the date hereof and at all times through the Closing Date (as if made on the Closing Date), of and compliance with all representations,
warranties and agreements of the Company contained herein, the performance by the Company of its obligations hereunder and the following
additional conditions:

(a) The Registration Statement
shall have become effective not later than 5:30 p.m., New York City time, on the date of this Agreement or such later date and time as
shall be consented to in writing by you, and, at each of the Closing Date and any Option Closing Date, no stop order suspending the effectiveness
of the Registration Statement or any post-effective amendment thereto has been issued under the Securities Act, no order preventing or
suspending the use of any Preliminary Prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been
instituted or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied with each request
(if any) from the Commission for additional information. The Prospectus containing the Rule 430A Information shall have been filed with
the Commission in the manner and within the time frame required by Rule 424(b) of the Securities Act Regulations (without reliance on
Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with, and declared effective by, the Commission
in accordance with the requirements of Rule 430A of the Securities Act Regulations.

(b) The Shares and the Representative
Warrant Shares shall be approved for listing on Nasdaq, subject to official notice of issuance and evidence of satisfactory distribution.

(c) FINRA shall have confirmed
that it has no objection to the fairness and reasonableness of the underwriting terms and arrangements.

(d) Prior to and on each of
the Closing Date and each Option Closing Date, if any: (i) there shall have been no Material Adverse Change from the latest dates as of
which such condition is set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus; (ii) no
action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any officer or director
of the Company before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision,
ruling or finding may reasonably be expected to result in a Material Adverse Change, except as set forth in the Registration Statement,
the Time of Sale Disclosure Package and the Final Prospectus; (iii) no stop order shall have been issued under the Securities Act and
no proceedings therefor shall have been initiated or threatened by the Commission; (iv) the Registration Statement, the Time of Sale Disclosure
Package and the Final Prospectus and any amendments or supplements thereto shall contain all material statements which are required to
be stated therein in accordance with the Securities Act and the rules and regulations thereunder and shall conform in all material respects
to the requirements of the Securities Act and the rules and regulations thereunder; (v) the Registration Statement nor any amendment or
supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein not misleading and (vi) the Time of Sale Disclosure Package nor the Final Prospectus nor any
amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading..

(e) On or after the date hereof
(i) no downgrading shall have occurred in the rating accorded any of the Company’s securities by any “nationally recognized
statistical organization,” as that term is defined by the Commission for purposes of Rule 436(g)(2) under the Securities Act, and
(ii) no such organization shall have publicly announced that it has under surveillance or review, with possible negative implications,
its rating of any of the Company’s securities.

(f) On the Closing Date, the
Representative shall have received the favorable opinion and negative assurance letter of Nelson Mullins Riley & Scarborough LLP,
counsel to the Company (“Company Counsel”), dated the Closing Date and addressed to the addressed to the Representative
as representative of the several Underwriters, in form and substance reasonably satisfactory to the Representative.